Cerebrospinal fluid orexin testing in Australians with narcolepsy type 1

Area of Science:

• Neurology
• Sleep Medicine
• Neurochemistry

Background:

• Narcolepsy type 1 diagnosis can be difficult, particularly differentiating it from other conditions based on clinical presentation alone.
• Cataplexy, a key symptom of narcolepsy type 1, can be challenging to identify or may be absent, complicating diagnosis.
• Cerebrospinal fluid (CSF) orexin testing is a specific biomarker for narcolepsy type 1 but is underutilized in the Australasian region.

Purpose of the Study:

• To describe the utilization and clinical utility of cerebrospinal fluid (CSF) orexin testing in diagnosing narcolepsy type 1 within the Australasian context.
• To evaluate the practical application of CSF orexin testing in a real-world clinical setting for patients with suspected narcolepsy type 1.
• To underscore the importance of CSF orexin testing as a diagnostic tool in regions where its use is limited.

Main Methods:

• Retrospective review of 15 patients undergoing CSF orexin testing at two sleep centers in Australasia.
• Analysis of clinical indications for testing, diagnostic outcomes, and the impact of CSF orexin levels on patient management.
• Focus on the practical aspects of sample collection, processing, and interpretation within the Australasian healthcare system.

Main Results:

• CSF orexin testing was performed in 15 patients with clinically suspected narcolepsy type 1.
• The results of CSF orexin testing provided valuable diagnostic information, aiding in the confirmation or exclusion of narcolepsy type 1.
• The study demonstrated the feasibility and utility of implementing CSF orexin testing in Australasian sleep centers.

Conclusions:

• Cerebrospinal fluid (CSF) orexin testing is a valuable and underutilized diagnostic tool for narcolepsy type 1 in Australasia.
• Implementing CSF orexin testing can improve diagnostic accuracy, particularly in complex cases.
• Increased utilization of CSF orexin testing is recommended to enhance the diagnosis and management of narcolepsy type 1 in the region.